×
QQQ   288.80 (+0.64%)
AAPL   142.92 (+0.96%)
MSFT   266.21 (+1.28%)
META   169.77 (+0.94%)
GOOGL   2,291.44 (+1.16%)
AMZN   114.33 (+0.73%)
TSLA   695.20 (-0.57%)
NVDA   151.30 (+1.11%)
NIO   20.83 (-6.09%)
BABA   119.12 (-0.84%)
AMD   75.35 (+0.20%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.57 (-0.74%)
F   11.06 (-1.25%)
DIS   96.08 (-1.13%)
AMC   12.57 (-1.64%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
QQQ   288.80 (+0.64%)
AAPL   142.92 (+0.96%)
MSFT   266.21 (+1.28%)
META   169.77 (+0.94%)
GOOGL   2,291.44 (+1.16%)
AMZN   114.33 (+0.73%)
TSLA   695.20 (-0.57%)
NVDA   151.30 (+1.11%)
NIO   20.83 (-6.09%)
BABA   119.12 (-0.84%)
AMD   75.35 (+0.20%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.57 (-0.74%)
F   11.06 (-1.25%)
DIS   96.08 (-1.13%)
AMC   12.57 (-1.64%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
QQQ   288.80 (+0.64%)
AAPL   142.92 (+0.96%)
MSFT   266.21 (+1.28%)
META   169.77 (+0.94%)
GOOGL   2,291.44 (+1.16%)
AMZN   114.33 (+0.73%)
TSLA   695.20 (-0.57%)
NVDA   151.30 (+1.11%)
NIO   20.83 (-6.09%)
BABA   119.12 (-0.84%)
AMD   75.35 (+0.20%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.57 (-0.74%)
F   11.06 (-1.25%)
DIS   96.08 (-1.13%)
AMC   12.57 (-1.64%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
QQQ   288.80 (+0.64%)
AAPL   142.92 (+0.96%)
MSFT   266.21 (+1.28%)
META   169.77 (+0.94%)
GOOGL   2,291.44 (+1.16%)
AMZN   114.33 (+0.73%)
TSLA   695.20 (-0.57%)
NVDA   151.30 (+1.11%)
NIO   20.83 (-6.09%)
BABA   119.12 (-0.84%)
AMD   75.35 (+0.20%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.57 (-0.74%)
F   11.06 (-1.25%)
DIS   96.08 (-1.13%)
AMC   12.57 (-1.64%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
NASDAQ:VYGR

Voyager Therapeutics Stock Forecast, Price & News

$6.18
-0.24 (-3.74%)
(As of 07/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.06
$6.75
50-Day Range
$4.82
$8.52
52-Week Range
$2.46
$10.60
Volume
372,609 shs
Average Volume
595,883 shs
Market Capitalization
$237.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
21.4% Upside
$7.50 Price Target
Short Interest
Healthy
3.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
0.35mentions of Voyager Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$2.66 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.71) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.24 out of 5 stars

Medical Sector

243rd out of 1,426 stocks

Biological Products, Except Diagnostic Industry

33rd out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Voyager Therapeutics logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Stock News Headlines

Looking Back In On Voyager Therapeutics
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
101
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/06/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+21.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$-71,200,000.00
Net Margins
-224.48%
Pretax Margin
-224.48%

Debt

Sales & Book Value

Annual Sales
$37.42 million
Book Value
$2.50 per share

Miscellaneous

Free Float
28,688,000
Market Cap
$237.66 million
Optionable
Optionable
Beta
1.06














Voyager Therapeutics Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Voyager Therapeutics stock.
View analyst ratings for Voyager Therapeutics
or view top-rated stocks.

What is Voyager Therapeutics' stock price forecast for 2022?

3 analysts have issued 1 year target prices for Voyager Therapeutics' stock. Their VYGR stock forecasts range from $6.00 to $9.00. On average, they expect Voyager Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Voyager Therapeutics' stock price performed in 2022?

Voyager Therapeutics' stock was trading at $2.71 at the beginning of 2022. Since then, VYGR shares have increased by 128.0% and is now trading at $6.18.
View the best growth stocks for 2022 here
.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.42. The firm earned $0.66 million during the quarter, compared to analyst estimates of $28.25 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 76.83% and a negative net margin of 224.48%.
View Voyager Therapeutics' earnings history
.

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Mr. Robert W. Hesslein, Sr. VP & Gen. Counsel (Age 69, Pay $576.62k)
  • Mr. G. Andre Turenne, Advisor (Age 48, Pay $600.3k)
  • Dr. Alfred W. Sandrock Jr., M.D., Ph.D., Pres, CEO & Director (Age 64)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder
  • Dr. Mark A. Kay M.D., Ph.D., Founder (Age 64)
  • Dr. Phillip D. Zamore, Founder
  • Ms. Julie Burek, VP of Fin. (Age 47) (LinkedIn Profile)
  • Ms. Robin Swartz, Chief Operating Officer (Age 51)
  • Ms. Michelle Quinn Smith, Chief HR Officer

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $6.18.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $237.66 million and generates $37.42 million in revenue each year. The company earns $-71,200,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Voyager Therapeutics have?

Voyager Therapeutics employs 101 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for Voyager Therapeutics is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.